BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 35417045)

  • 21. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proteasomal down-regulation of the proapoptotic MST2 pathway contributes to BRAF inhibitor resistance in melanoma.
    Romano D; García-Gutiérrez L; Aboud N; Duffy DJ; Flaherty KT; Frederick DT; Kolch W; Matallanas D
    Life Sci Alliance; 2022 Oct; 5(10):. PubMed ID: 36038253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.
    Anastas JN; Kulikauskas RM; Tamir T; Rizos H; Long GV; von Euw EM; Yang PT; Chen HW; Haydu L; Toroni RA; Lucero OM; Chien AJ; Moon RT
    J Clin Invest; 2014 Jul; 124(7):2877-90. PubMed ID: 24865425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.
    Sakaizawa K; Ashida A; Uchiyama A; Ito T; Fujisawa Y; Ogata D; Matsushita S; Fujii K; Fukushima S; Shibayama Y; Hatta N; Takenouchi T; Uehara J; Okuyama R; Yamazaki N; Uhara H
    J Dermatol Sci; 2015 Oct; 80(1):33-7. PubMed ID: 26282084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteogenomics Reveals Perturbed Signaling Networks in Malignant Melanoma Cells Resistant to BRAF Inhibition.
    Schmitt M; Sinnberg T; Bratl K; Zittlau K; Garbe C; Macek B; Nalpas NC
    Mol Cell Proteomics; 2021; 20():100163. PubMed ID: 34673281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition.
    Sharma R; Fedorenko I; Spence PT; Sondak VK; Smalley KS; Koomen JM
    J Proteome Res; 2016 Dec; 15(12):4476-4489. PubMed ID: 27934295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
    Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
    Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
    Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor.
    Kaplan FM; Kugel CH; Dadpey N; Shao Y; Abel EV; Aplin AE
    J Biol Chem; 2012 Dec; 287(50):41797-807. PubMed ID: 23076151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.
    Raaijmakers MI; Widmer DS; Narechania A; Eichhoff O; Freiberger SN; Wenzina J; Cheng PF; Mihic-Probst D; Desalle R; Dummer R; Levesque MP
    Oncotarget; 2016 Nov; 7(47):77163-77174. PubMed ID: 27791198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAF
    Barceló C; Sisó P; Maiques O; García-Mulero S; Sanz-Pamplona R; Navaridas R; Megino C; Felip I; Urdanibia I; Eritja N; Soria X; Piulats JM; Penin RM; Dolcet X; Matías-Guiu X; Martí RM; Macià A
    J Invest Dermatol; 2020 Jun; 140(6):1253-1265. PubMed ID: 31877318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma.
    Marusak C; Thakur V; Li Y; Freitas JT; Zmina PM; Thakur VS; Chang M; Gao M; Tan J; Xiao M; Lu Y; Mills GB; Flaherty K; Frederick DT; Miao B; Sullivan RJ; Moll T; Boland GM; Herlyn M; Zhang G; Bedogni B
    Clin Cancer Res; 2020 Nov; 26(22):6039-6050. PubMed ID: 32820016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
    Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
    Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.
    Das I; Wilhelm M; Höiom V; Franco Marquez R; Costa Svedman F; Hansson J; Tuominen R; Egyhàzi Brage S
    Cell Death Dis; 2019 Sep; 10(9):663. PubMed ID: 31506424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.
    Kakavand H; Walker E; Lum T; Wilmott JS; Selinger CI; Smith E; Saw RP; Yu B; Cooper WA; Long GV; O'Toole SA; Scolyer RA
    Histopathology; 2016 Oct; 69(4):680-6. PubMed ID: 27151331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mitochondrial oxidative phosphorylation controls cancer cell's life and death decisions upon exposure to MAPK inhibitors.
    Corazao-Rozas P; Guerreschi P; André F; Gabert PE; Lancel S; Dekiouk S; Fontaine D; Tardivel M; Savina A; Quesnel B; Mortier L; Marchetti P; Kluza J
    Oncotarget; 2016 Jun; 7(26):39473-39485. PubMed ID: 27250023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.
    Basile KJ; Le K; Hartsough EJ; Aplin AE
    Pigment Cell Melanoma Res; 2014 May; 27(3):479-84. PubMed ID: 24422853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.
    Margue C; Philippidou D; Kozar I; Cesi G; Felten P; Kulms D; Letellier E; Haan C; Kreis S
    J Exp Clin Cancer Res; 2019 Feb; 38(1):56. PubMed ID: 30728057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor.
    Caporali S; Alvino E; Lacal PM; Levati L; Giurato G; Memoli D; Caprini E; Antonini Cappellini GC; D'Atri S
    Int J Oncol; 2016 Sep; 49(3):1164-74. PubMed ID: 27572607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.